nangibotide

DRUG2 trials

Sponsors

Inotrem

Conditions

COVID19Healthy Subjects

Phase 1

Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects

CompletedNCT03463044

InotremHealthy Subjects

Start: 2016-04-01End: 2016-08-25Updated: 2025-02-10

Phase 2

Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support

CompletedNCT04429334

Start: 2020-09-23End: 2022-06-22Updated: 2023-05-03

Related Papers

Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial.

2023-05-3111 citations